Article Text

Download PDFPDF
Case report
Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge
  1. Irene Alejandra Orbe Jaramillo1,
  2. Carmen De Lucas Collantes2,
  3. Amelia Martínez de Azagra3 and
  4. Elena Sebastián4
  1. 1Hematology, Hospital Universitario de Mostoles, Mostoles, Madrid, Spain
  2. 2Department of Nephrology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
  3. 3Intensive Care Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
  4. 4Onco-Hematology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
  1. Correspondence to Dr Irene Alejandra Orbe Jaramillo; alejandra251{at}msn.com

Abstract

Thrombotic thrombocytopaenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterised by microangiopathic haemolytic anaemia, thrombocytopaenia and organ ischaemia. TTP is caused by a severe functional deficiency of ADAMTS13 activity. We describe a 10-year-old girl presenting anaemia and thrombocytopaenia with schistocytes. Urine protein to creatinine ratio was within nephrotic range. ADAMTS13 activity was 0%, and no anti-ADAMTS13 antibodies were found. A renal biopsy showed deposits of IgG, C3 and C1q in the capillary membrane, compatible with class V lupus nephritis. Therapeutic plasma exchange (TPE) was performed in conjunction with therapy consisting of steroids and mycophenolate mofetil. After 11 months of follow-up, the patient remains in remission with normal ADAMTS13 activity. Although acquired TTP is a rare finding in children, differential diagnosis of thrombotic microangiopathy should include ADAMTS13 and the assay should be performed early. TTP treatment is based on TPE, although the underlying disease must be ruled out to optimise treatment and prevent relapse.

  • haematology (drugs and medicines)
  • paediatric prescribing

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors IAOJ: summary of clinical record, writing and editing. CDLC: design. AMA: review. ES: writing, review and translation.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.